Article Text

PDF
Pigmentary macular dystrophy in spinocerebellar ataxia type 1
  1. Y Saito1,
  2. K Matsumura1,
  3. S Shimizu2,
  4. Y Ichikawa3,
  5. K Ochiai4,
  6. J Goto5,
  7. S Tsuji5,
  8. T Shimizu6
  1. 1Department of Neurology, Teikyo University School of Medicine, Kaga, Itabashi-ku, Tokyo, Japan
  2. 2Department of Ophthalmology, Teikyo University School of Medicine
  3. 3Department of Neurology, Graduate School of Medicine and Faculty of Medicine, University of Tokyo, Tokyo
  4. 4Department of Ophthalmology, Teikyo University School of Medicine
  5. 5Department of Neurology, Graduate School of Medicine and Faculty of Medicine
  6. 6Department of Neurology, Teikyo University School of Medicine
  1. Correspondence to:
 K Matsumura
 Department of Neurology, Teikyo Univercity School of Medicine, 2-11-1 Kaga, Itabashi-Ku, Tokyo, 173-8605, Japan;k-matsu{at}med.teikyo-u.ac.jp

Statistics from Altmetric.com

Spinocerebellar ataxia type 1 (SCA1) is an autosomal-dominant, late-onset, slowly progressive disorder, primarily characterised by a gradual loss of motor coordination, resulting from dysfunction and degeneration of the cerebellum and its connecting pathways.1,2 This disease is caused by expansion of a CAG trinucleotide repeat within the SCA1 gene, which encodes a protein called ataxin-1.1,2 The first and most typical neurological symptom of SCA1 is cerebellar ataxia. Additional symptoms comprise the slowing of saccades, ophthalmoplegia, dysarthria, pyramidal sign and involuntary movement.1,2 As regards ophthalmological abnormalities of SCA1, decreased visual acuity owing to optic atrophy, attenuation of oscillatory potentials of electroretinogram and enlargement of corneal endothelial cells have been reported.3 Hence, pigmentary macular dystrophy (PMD) has not been recognised as a clinical feature of SCA1, although it is well established as a major symptom of spinocerebellar ataxia type 7 (SCA7), which is caused by expansion of a …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.